- Home
- AURE vs SYBX Comparison
AURE vs SYBX Comparison
Compare AURE & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AURE
- SYBX
- Stock Information
- Founded
- AURE 2018
- SYBX N/A
- Country
- AURE Hong Kong
- SYBX United States
- Employees
- AURE N/A
- SYBX N/A
- Industry
- AURE Finance: Consumer Services
- SYBX Biotechnology: Pharmaceutical Preparations
- Sector
- AURE Finance
- SYBX Health Care
- Exchange
- AURE Nasdaq
- SYBX Nasdaq
- Market Cap
- AURE 19.4M
- SYBX 20.0M
- IPO Year
- AURE N/A
- SYBX N/A
- Fundamental
- Price
- AURE $0.42
- SYBX $1.77
- Analyst Decision
- AURE
- SYBX
- Analyst Count
- AURE 0
- SYBX 0
- Target Price
- AURE N/A
- SYBX N/A
- AVG Volume (30 Days)
- AURE 3.1M
- SYBX 37.4K
- Earning Date
- AURE 02-13-2026
- SYBX 11-11-2025
- Dividend Yield
- AURE N/A
- SYBX N/A
- EPS Growth
- AURE N/A
- SYBX N/A
- EPS
- AURE N/A
- SYBX N/A
- Revenue
- AURE $142,570.00
- SYBX N/A
- Revenue This Year
- AURE N/A
- SYBX N/A
- Revenue Next Year
- AURE N/A
- SYBX N/A
- P/E Ratio
- AURE N/A
- SYBX N/A
- Revenue Growth
- AURE N/A
- SYBX N/A
- 52 Week Low
- AURE $0.31
- SYBX $0.90
- 52 Week High
- AURE $2.70
- SYBX $1.96
- Technical
- Relative Strength Index (RSI)
- AURE N/A
- SYBX 55.49
- Support Level
- AURE N/A
- SYBX $1.64
- Resistance Level
- AURE N/A
- SYBX $1.80
- Average True Range (ATR)
- AURE 0.00
- SYBX 0.10
- MACD
- AURE 0.00
- SYBX 0.00
- Stochastic Oscillator
- AURE 0.00
- SYBX 64.91
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.